Published in

Journal of Rheumatology, The Journal of Rheumatology, Suppl 2(50), p. 27-30, 2023

DOI: 10.3899/jrheum.2023-0521

Links

Tools

Export citation

Search in Google Scholar

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis

Journal article published in 2023 by Philip J. Mease ORCID, Peter Nash ORCID, Suzanne Grieb ORCID, Vinod Chandran ORCID
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Given the impact of the coronavirus disease 2019 (COVID-19) on patients with psoriatic disease (PsD), a session was devoted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting to discussing the current understanding of the risk of severe COVID-19 in patients with PsD. The effects of PsD and its treatment on prevention and treatment of COVID-19 with vaccinations, antiviral drugs, and monoclonal antibodies were discussed. The session concluded with a presentation on the perspectives of patient research partners about their experiences with COVID-19.